Oprozomib Found Active in Multiple Myeloma, Waldenström Macroglobulinemia
More work is needed to improve drug formulations for treatments for Waldenström macroglobulinemia.
Waldenstrom Macroglobulinemia
Using a Risk-Based System to Predict Progression From Asymptomatic Waldenström Macroglobulinemia
The model stratified patients into 3 risk groups based on median time to disease progression.
Measuring Patient-Reported Outcomes in Waldenström Macroglobulinemia Patients Receiving Rituximab vs Ibrutinib-Rituximab
Researchers sought to further evaluate data on patient-reported outcomes from the iNNOVATE study.
Bendamustine-Rituximab-Bortezomib Promising in R/R Waldenström Macroglobulinemia
High rates of PFS found with salvage treatment with BRB regimen in patients with R/R Waldenström macroglobulinemia.
Ibrutinib Dose Reduction Did Not Affect PFS in Waldenström Macroglobulinemia
The need for dose reductions did not significantly affect progression-free survival in patients with WM treated with ibrutinib.
Long-Term Data Show Low Risk of Second Primary Malignancy, Transformation in WM
Study shows risk of second primary malignancy or transformation to lymphoma is low.
Next-Generation Sequencing Helped Identify Pathways for Transformation of WM to DLBCL
IGHV analysis demonstrated that DLBCL tissue was clonally related to the antecedent WM clone.
BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
BeiGene released results from its phase 1 clinical trial of the investigational BTK inhibitor zanubrutinib.
Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
Carfilzomib-based regimens are well tolerated and offer a neuropathy-sparing approach in newly diagnosed MM and WM.
Pivotal Trial Underway for Zanubrutinib in Waldenström Macroglobulinemia
The safety and efficacy of investigational agent zanubrutinib is being evaluated in a head-to-head phase 3 trial in Waldenström macroglobulinemia.
-
Loading...
-
Loading...
Next post in Hematologic Cancers
